Here are 1-3 brief analogies for Kodiak Sciences (KOD):

• A challenger biotech striving to be the next Regeneron (REGN) or Roche (RHHBY) in long-lasting eye disease treatments.
• Like a clinical-stage Regeneron (REGN) focused on developing extended-duration therapies for wet AMD and other retinal diseases.
• A specialized biotech aiming to unseat established players like Regeneron (REGN) in the anti-VEGF market with potentially more durable eye disease drugs.

• Tarcocimab tedromer (KSI-501): An investigational antibody biopolymer conjugate developed for the long-term treatment of major retinal vascular diseases, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

Kodiak Sciences (KOD) is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly its lead product candidate tarcocimab (KSI-301).

As of its most recent financial filings, Kodiak Sciences does not have any commercial products approved for sale. Consequently, the company does not currently have major customers in the traditional sense of companies or individuals purchasing its products. Its revenue streams primarily consist of investment income and proceeds from financing activities (such as equity offerings) to fund its ongoing research and development efforts.

• Thermo Fisher Scientific (TMO)

Victor Perlroth, M.D. Chairman and Chief Executive Officer. Dr. Perlroth co-founded Kodiak Sciences in 2009. He previously co-founded Avidia Inc. in 2003, a biopharmaceuticals company that was acquired by Amgen for $450 million, where he was one of two principals involved in the acquisition. He also served as Venture Partner and Entrepreneur in Residence at MPM Capital, a healthcare venture capital firm, and as Chief Operating Officer at Guzik Technical Enterprises.

John Borgeson Executive Vice President and Chief Financial Officer. Mr. Borgeson has served as CFO since June 2014. He previously led finance for private biotech companies, including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals for $825 million. Mr. Borgeson was also a Vice President of Finance at Pfizer Inc., where his roles included CFO for Pfizer's biotherapeutics division and corporate tax executive. He also served as CFO of venBio, a venture capital firm.

Jason Ehrlich, M.D., Ph.D. Chief Medical Officer & Chief Development Officer. Dr. Ehrlich is recognized for his leadership in ophthalmic drug development. Before joining Kodiak, he served as Global Head, Clinical Ophthalmology at Genentech, a member of the Roche Group, from 2008 to 2018. During his time there, he oversaw the global development of lampalizumab and led efforts for Lucentis in diabetic eye disease, contributing to FDA approvals. He also guided the integration of ForSIGHT VISION4 after its acquisition by Genentech/Roche.

Dolly S. Chang, M.D., M.P.H., Ph.D. Chief Scientific Officer.

Almas Qudrat, M.Sc. Chief Quality Officer.

The rapid market adoption and success of rival anti-VEGF treatments offering extended dosing intervals, specifically Roche's Vabysmo (faricimab) and Regeneron's high-dose Eylea (aflibercept 8mg, branded as Eylea HD).

Kodiak Sciences' lead investigational drug, tarcocimab tedromer (KSI-301), was initially designed with the aim of providing extended durability and reducing the frequency of injections for retinal diseases like wet Age-related Macular Degeneration (AMD). However, the pivotal DAZZLE study for wet AMD failed to meet its primary endpoint of non-inferiority to Eylea at 12-week dosing, significantly undermining this key differentiation point.

In contrast, Vabysmo, approved in 2022, and Eylea HD, approved in 2023, have successfully demonstrated and received regulatory approval for extended dosing intervals (up to 4 months). These treatments are rapidly establishing themselves as the new standard for convenience and reduced injection burden in the anti-VEGF market. This directly threatens Kodiak's potential market entry as these competitors are capturing significant market share and setting a higher bar for extended dosing, making it challenging for tarcocimab to compete effectively with its originally intended value proposition.

Kodiak Sciences (KOD) focuses on developing treatments for high-prevalence retinal diseases, with their main product candidates being tarcocimab tedromer, KSI-501, and KSI-101.

For their pipeline candidates tarcocimab tedromer and KSI-501, which target diabetic retinopathy (DR), retinal vein occlusion (RVO), and wet age-related macular degeneration (AMD), the total addressable market (TAM) is estimated to be approximately $18 billion by 2028. Another estimate places the anti-VEGF marketplace at $15 billion. Approximately 60% of the $18 billion market is in the U.S. alone.

For KSI-101, which is being developed for Macular Edema Secondary to Inflammation (MESI), the market is described as a "greenfield market opportunity" and a "new market segment separate from the established anti-VEGF market". While a specific monetary value for the MESI market is not provided, intraocular inflammation, which can lead to macular edema, is the fourth leading cause of vision loss in the developed world.

1. Launch and Market Penetration of Tarcocimab (KSI-301): Tarcocimab, an anti-VEGF antibody biopolymer conjugate, is Kodiak Sciences' lead product candidate. It has successfully completed three Phase 3 studies across diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration (wet AMD). The company anticipates topline data for the GLOW2 diabetic retinopathy study in the first quarter of 2026 and for the DAYBREAK wet AMD study in the third quarter of 2026. Kodiak Sciences aims for a single Biologics License Application (BLA) filing in 2026 for these three major indications. This product is designed to offer both strong immediacy and prolonged durability, positioning it as a potential "mainstay" intravitreal biologic in the treatment of prevalent retinal vascular diseases.
2. Launch and Market Penetration of KSI-501: KSI-501 is a bispecific anti-interleukin-6 (IL-6) and VEGF-trap antibody biopolymer conjugate. This therapy is designed to address both abnormal angiogenesis and inflammation, potentially offering a new category of retinal medicine with enhanced therapeutic efficacy and durability in high-prevalence retinal vascular diseases. Kodiak Sciences plans to rapidly advance KSI-501 into pivotal studies.
3. Launch and Market Penetration of KSI-101 for Macular Edema Secondary to Inflammation (MESI): KSI-101 (KSI-501P) is an unconjugated bispecific protein targeting both IL-6 and VEGF, developed for patients experiencing retinal fluid and inflammation. Following the initiation of its APEX Phase 1b clinical study in the first half of 2024, Kodiak Sciences expects to commence a pivotal study for KSI-101 in patients with MESI in the second quarter of 2025. The company views this as a "greenfield market opportunity".

Capital Allocation Decisions (Last 3-5 Years) for Kodiak Sciences (KOD)

• No significant share repurchase programs or activities with disclosed dollar amounts were found in the last 3-5 years.

• In November 2020, Kodiak Sciences completed an underwritten public offering of 5,972,222 shares of its common stock at $108.00 per share, resulting in approximately $645.0 million in gross proceeds.
• As of February 28, 2025, Kodiak Sciences had 52,748,343 shares of common stock outstanding.

• In December 2019, Kodiak Sciences entered into a funding agreement with Baker Bros. Advisors, LP (BBA) to sell a capped royalty right on global net sales of tarcocimab (KSI-301) for $225.0 million in committed development funding.
• The initial $100.0 million of this funding was payable at the closing of the transaction (expected January 10, 2020), with the remaining $125.0 million contingent upon achieving 50% enrollment in planned pivotal clinical studies.

• Kodiak Sciences has made no investments or acquisitions in other companies.

• Kodiak Sciences, in collaboration with Lonza Ltd, constructed the "Ursus Facility," a custom-built manufacturing facility for the commercial-scale production of Kodiak's drug substance.
• The Ursus facility achieved mechanical completion in March 2022 and commenced manufacturing of commercial-scale cGMP batches in the first quarter of 2023.
• The company is also investing in developing prefilled syringe technology and new LIDAR- and OCT-based retinal headset technologies to support clinical trials.